Alpha-2 HS Glycoprotein in Multiple Myeloma and Hypercalcaemia
Author Information
Author(s): S.M. Crawford
Primary Institution: Bradford Royal Infirmary
Hypothesis
What is the relationship between serum alpha-2 HS glycoprotein levels and hypercalcaemia in patients with multiple myeloma?
Conclusion
Patients with multiple myeloma do not differ in serum alpha-2 HS glycoprotein levels from a normal group, but levels significantly drop in the presence of hypercalcaemia.
Supporting Evidence
- Serum alpha-2 HS glycoprotein levels were measured in patients with multiple myeloma and hypercalcaemia.
- Patients with hypercalcaemia due to malignancy had lower alpha-2 HS levels compared to controls.
- The study found no significant difference in alpha-2 HS levels between myeloma patients and the control group.
Takeaway
This study looked at a protein in the blood of people with a type of cancer called multiple myeloma. It found that when these patients have high calcium levels, the protein level goes down.
Methodology
Serum levels of alpha-2 HS glycoprotein were measured in patients with multiple myeloma and hypercalcaemia using single radial immunodiffusion.
Limitations
The study had a small sample size and did not explore the physiological role of alpha-2 HS glycoprotein in detail.
Participant Demographics
28 patients with multiple myeloma and 4 patients with hypercalcaemia due to disseminated carcinoma, plus a control group of 18 students.
Statistical Information
P-Value
0.0001
Statistical Significance
p=0.0001
Want to read the original?
Access the complete publication on the publisher's website